• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Masimo Corporation

    6/10/26 4:22:57 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email
    S-8 POS 1 tm2617396d9_s8pos.htm S-8 POS

     

    As filed with the Securities and Exchange Commission on June 10, 2026

     

    Registration No. 333-240152

    Registration No. 333-234386

    Registration No. 333-219207

    Registration No. 333-194089

    Registration No. 333-186692

    Registration No. 333-179557

    Registration No. 333-168534

    Registration No. 333-157673

    Registration No. 333-149138

    Registration No. 333-148149

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-240152

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-234386

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-219207

    Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-194089

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-186692

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-179557

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-168534

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-157673

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-149138

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-148149

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    MASIMO CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   33-0368882
    (State or other jurisdiction of incorporation)   (IRS Employer Identification No.)

     

    52 Discovery

    Irvine, California 92618

    (949) 297-7000

    (Address, including zip code, and telephone number, including area code of principal executive offices)

     

     

    Masimo Corporation 2017 Equity Incentive Plan, as amended

    Masimo Corporation 2007 Stock Incentive Plan

    Masimo Retirement Savings Plan

    (Full title of the plans)

     

    Micah Young

    EVP, Chief Financial Officer

    Masimo Corporation

    52 Discovery
    Irvine, California 92618

    (949) 297-7000

    (Name and address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Daniel Wolf, P.C.

    David M. Klein, P.C.

    Brian H. Junquera

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, New York 10022

    (212) 446-4800

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   x   Accelerated filer   ¨
           
    Non-accelerated filer   ¨   Smaller reporting company   ¨
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

     

    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

     

    This Post-Effective Amendment (the “Post-Effective Amendment”) to the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) is being filed to withdraw and deregister: all shares of common stock, par value $0.001 per share (the “Common Stock”), of Masimo Corporation (the “Registrant”) that had been registered and remain unsold under the Registration Statements, together with any and all plan interests and other securities registered thereunder (note that the share numbers listed below do not take into account corporate actions, such as stock splits, taken in the interim):

     

    ·Registration Statement 333-219207, originally filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on July 7, 2017, and as amended by Registration Statement 333-240152 on Form S-8, originally filed by the Registrant with the SEC on July 28, 2020, registering 7,500,000 shares of Common Stock under the Masimo Corporation 2017 Equity Incentive Plan (as amended) (the “2017 Plan”).

     

    ·Registration Statement 333-149138 on Form S-8, originally filed by the Registrant with the SEC on February 11, 2008, and as amended by Registration Statement 333-234386 on Form S-8, originally filed by the Company with the SEC on October 30, 2019, registering (i) 1,250,000 shares of Common Stock purchased from time to time under the Masimo Retirement Savings Plan (the “401(k) Plan”) by the Trustee (as defined in the 401(k) Plan) with contributions made by the Registrant and its participating subsidiaries and with salary deferrals by participants who may elect to invest in the Registrant’s Common Stock Fund (as defined in the 401(k) Plan); and (ii) an indeterminate amount of plan interests issuable under the 401(k) Plan.

     

    ·Registration Statement 333-148149 on Form S-8, originally filed by the Registrant with the SEC on December 19, 2007, as amended by Registration Statement 333-157673 on Form S-8, originally filed with the SEC on March 4, 2009, as amended by Registration Statement 333-168534 on Form S-8, originally filed with the SEC on August 4, 2010, as amended by Registration Statement 333-179557 on Form S-8, originally filed with the SEC on February 17, 2012, as amended by Registration Statement 333-186692 on Form S-8, originally filed with the SEC on February 15, 2013, as amended by Registration Statement 333-194089 on Form S-8, originally filed by the Registrant with the SEC on February 24, 2014, as amended by Post-Effective Amendment No. 1 on Form S-8, File No. 333-194089, filed with the SEC on July 7, 2017, registering 1,278,627 shares of Common Stock under the Masimo Corporation 2007 Stock Incentive Plan.

     

    On June 10, 2026, pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of February 16, 2026, by and among the Registrant, Danaher Corporation, a Delaware corporation (“Parent”), and Mobius Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and a wholly owned subsidiary of Parent.

     

    As a result of the transactions contemplated by the Merger Agreement, all offerings of securities registered pursuant to the Registration Statements have been terminated. In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold at the termination of the respective offering, the Registrant hereby removes from registration all of the securities registered but unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.

     

    The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by the Merger Agreement, which is included as Exhibit 2.1 in the Registrant’s Form 8-K filed with the SEC on February 17, 2026.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”) the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on June 10, 2026.

     

      MASIMO CORPORATION
         
      By: /s/ Micah Young
        Name: Micah Young
        Title: EVP, Chief Financial Officer

     

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act.

     

     

     

    Get the next $MASI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    3/27/2026Outperform → Mkt Perform
    Raymond James
    11/17/2025Neutral
    BofA Securities
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    More analyst ratings

    $MASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Solomon Darlene J. S. returned $542,700 worth of shares to the company (3,015 units at $180.00), closing all direct ownership in the company (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    6/12/26 4:40:25 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Scannell Timothy J returned $469,440 worth of shares to the company (2,608 units at $180.00), closing all direct ownership in the company (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    6/12/26 4:39:49 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lane Wendy E returned $469,440 worth of shares to the company (2,608 units at $180.00), closing all direct ownership in the company (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    6/12/26 4:39:10 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Masimo downgraded by Raymond James

    Raymond James downgraded Masimo from Outperform to Mkt Perform

    3/27/26 8:44:43 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BofA Securities initiated coverage on Masimo

    BofA Securities initiated coverage of Masimo with a rating of Neutral

    11/17/25 9:40:41 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Raymond James reiterated coverage on Masimo with a new price target

    Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

    12/27/24 7:29:29 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    SEC Filings

    View All

    SEC Form 15-12G filed by Masimo Corporation

    15-12G - MASIMO CORP (0000937556) (Filer)

    6/22/26 4:57:34 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 POS filed by Masimo Corporation

    S-8 POS - MASIMO CORP (0000937556) (Filer)

    6/10/26 4:24:21 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 POS filed by Masimo Corporation

    S-8 POS - MASIMO CORP (0000937556) (Filer)

    6/10/26 4:22:57 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sirius XM Holdings Set to Join S&P MidCap 400

    NEW YORK, June 8, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11. S&P 500 & 100 constituent Danaher Corp. (NYSE:DHR) is acquiring Masimo in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector  June 11, 2026  S&P MidCap 400 Addition Sirius XM HoldingsSIRI Communication Services  June 11, 2026  S&P MidCap 400 Deletion MasimoMASI Health Care ABOUT S&P DOW JONES INDICESS&P Dow Jon

    6/8/26 6:09:00 PM ET
    $DHR
    $MASI
    $SIRI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Shareholders Approve Acquisition by Danaher

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026 (the "Merger Agreement"), by and among Masimo, Danaher Corporation ("Danaher") (NYSE:DHR) and Mobius Merger Sub, Inc. (the "Merger Sub") at Masimo's special meeting of stockholders held virtually on May 1, 2026 (the "Special Meeting"). Katie Szyman, Chief Executive Officer of Masimo, stated: "We thank our shareholders for their strong support of this important milestone for Masimo. The Merger delivers compelling value and positions Masimo fo

    5/4/26 9:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study

    NICU Study Adds to the Evidence Demonstrating SET®'s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ:MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and D

    4/28/26 8:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Leadership Updates

    Live Leadership Updates

    View All

    Sirius XM Holdings Set to Join S&P MidCap 400

    NEW YORK, June 8, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11. S&P 500 & 100 constituent Danaher Corp. (NYSE:DHR) is acquiring Masimo in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector  June 11, 2026  S&P MidCap 400 Addition Sirius XM HoldingsSIRI Communication Services  June 11, 2026  S&P MidCap 400 Deletion MasimoMASI Health Care ABOUT S&P DOW JONES INDICESS&P Dow Jon

    6/8/26 6:09:00 PM ET
    $DHR
    $MASI
    $SIRI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board

    BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors. These leadership appointments reflect a pivotal moment for Clairity following FDA De Novo authorization of its mammography-based AI risk prediction platform and increasing engagement with health systems and partners worldwide. Clairity's innovation aligns with national priorities to improve health o

    1/21/26 4:30:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $437,940 worth of shares (3,000 units at $145.98), increasing direct ownership by 168% to 4,790 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/12/25 4:20:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Financials

    Live finance-specific insights

    View All

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link (Please register to obtain the dial-in number): Masim

    2/12/26 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Announces Select Preliminary 2025 Financial Results

    Complete fourth quarter and full-year 2025 financial results will be announced on Thursday, February 26, 2026 Masimo Corporation (NASDAQ:MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. Preliminary Fourth Quarter 2025 Financial Results:   •   Revenue is expected to be approximately $411 million, representing approximately 12% growth on a reported basis and 11% growth on a constant currency basis(1);   •   Non-GAAP earnings per diluted share(2), including the impact of new tariffs, are expected to be more than $1.54; and   •   Shipments of noninv

    1/12/26 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    9/25/24 4:01:23 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    8/30/24 4:56:53 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    7/17/24 5:29:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care